Cancer Immunology Reserch

ATF7ip inhibits the tumor immune response by promoting terminal CD8+ T cell Exhaustion

by

Cancer Immunol Res. 2026 Apr 13. doi: 10.1158/2326-6066.CIR-25-0816. Online ahead of print. ABSTRACT CD8+ T cell exhaustion limits the immune response to tumors because of ineffective T cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. Here, we identified activating … Read more

DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL-33-Mediated M2-like Polarization of Tumor-Associated Macrophages

by

Cancer Immunol Res. 2026 Apr 10. doi: 10.1158/2326-6066.CIR-25-1073. Online ahead of print. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with low immunotherapy efficacy due to an immunosuppressive tumor microenvironment in proficient mismatch repair (pMMR) disease, which accounts for most cases of CRC. Herine, we have identified discoidin domain receptor 1 (DDR1) … Read more

Tumor-infiltrating platelets recruit neutrophils to promote tumor growth through the 5-HIAA-GPR35-ERK1/2 axis in Hepatocellular Carcinoma

by

Cancer Immunol Res. 2026 Apr 10. doi: 10.1158/2326-6066.CIR-25-0498. Online ahead of print. ABSTRACT Tumor-associated neutrophils (TANs) promote tumor growth and metastasis in hepatocellular carcinoma (HCC). Platelets can activate neutrophils and contribute to inflammation and organ damage; however, the relationship between TANs and platelets in HCC remains unclear. We performed multiplex immunohistochemistry and found that tumor-infiltrating … Read more

B Cells and Tertiary Lymphoid Structures as Integral Components of the Cancer Immunity Cycle

by

Cancer Immunol Res. 2026 Mar 31:OF1-OF2. doi: 10.1158/2326-6066.CIR-26-0311. Online ahead of print. ABSTRACT The influence B cells have in the tumor microenvironment has historically remained unresolved across solid tumors. At the same time, numerous findings of ectopic germinal centers in inflamed tumors containing tertiary lymphoid structures have been the impetus for redefining what effective antitumor … Read more

Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)

by

Cancer Immunol Res. 2026 Mar 30. doi: 10.1158/2326-6066.CIR-25-1194. Online ahead of print. ABSTRACT Patients with bulky, unresectable stage III non-small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. … Read more

Reduced tumor control in males can result from impaired CD4+ T-cell help through the CD40L-CD40 pathway

by

Cancer Immunol Res. 2026 Mar 25. doi: 10.1158/2326-6066.CIR-25-1115. Online ahead of print. ABSTRACT Sex-based differences in cancer incidence are incompletely understood, but potential roles for the immune system are beginning to emerge. CD4+ T cells play a central role in coordinating antitumor immunity. In addition to cytokine production, CD40L expression on CD4+ T cells provides … Read more

Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells

by

Cancer Immunol Res. 2026 Mar 20. doi: 10.1158/2326-6066.CIR-25-0609. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T cells have robust antitumor activity against hematologic malignancies and have the potential to benefit patients with solid tumors. Immune recognition of murine proteins expressed in adoptively transferred T cells and lack of homeostatic cytokines in the tumor … Read more

HTRA1+ macrophages induce T cells egress through CRIP1/NF-κB/CXCL12 to limit the effects of immunotherapy in triple-negative breast cancer

by

Cancer Immunol Res. 2026 Mar 19. doi: 10.1158/2326-6066.CIR-25-1138. Online ahead of print. ABSTRACT The variation in immunotherapy responses among patients with triple-negative breast cancer (TNBC) is attributed to the high heterogeneity of tumor immune components, in which macrophages play a key role. Hence, identification of key macrophage subpopulations associated with immunotherapy efficacy could provide important … Read more

FOXM1-specific TCR-engineered T cells target non-small cell lung cancer

by

Cancer Immunol Res. 2026 Mar 19. doi: 10.1158/2326-6066.CIR-25-0605. Online ahead of print. ABSTRACT FOXM1 is highly expressed in various cancer types and considered a key driver of cancer progression. Accordingly, we evaluated the immunogenicity of FOXM1 and investigated the feasibility of targeting this transcription factor using T cell receptor (TCR) engineering. We identified epitopes derived … Read more

Error: Connection timed out (110)